Why the study?
Does ursodeoxycholic acid improve endothelium-dependent and -independent vasodilatation in patients with coronary heart disease?
Does ursodeoxycholic acid improve endothelium-dependent and -independent vasodilatation in patients with coronary heart disease?
Six weeks of ursodeoxycholic acid therapy improves endothelium-dependent, nitric oxide-independent vasodilatation in patients with coronary heart disease.
Answers are grounded in this paper and cite their sources.
UDCA augments endothelium-dependent vasodilatation in CHD; extends RCT evidence to NO-independent pathways.
AIMS: Ursodeoxycholic acid (UDCA) has cholesterol lowering and anti-inflammatory effects and bile acids are reported to exert vasodilator effects; all of these properties might be considered desirable in a drug used in the treatment of patients with coronary heart disease. We investigated a hypothesis that UDCA may dilate arteries and the mechanism of action. METHODS: We evaluated effects of a 6-week treatment with UDCA in 11 coronary heart disease patients on endothelium-dependent (acetylcholine-induced) and -independent (nitroprusside-induced) vasodilatations in forearm vasculature by strain-gauge plethysmography. Healthy individuals (n=14) served as baseline controls. RESULTS: The percentage increase by acetylcholine in the flow of the infused arm relative to the non-infused arm of coronary heart disease patients during the trial remained unaltered, but vasodilatation to NG-monomethyl-l-arginine+acetylcholine was improved by 161+/-27% with UDCA vs 83+/-22% with placebo (mean difference 91% [95% CI 35%, 147%], P=0.016). CONCLUSIONS: Six weeks' UDCA therapy improved endothelium-dependent nitric oxide-independent vasodilatation, which might maintain arterial flow in coronary heart disease patients under conditions of impaired nitric oxide production.
No takes yet. Share an insight, caveat, or question.
Sinisalo et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: